Abstract:Aim: To discover novel ligands of estrogen receptor (ER) β using pharmacophore mapping and structure-based screening. Methods: A computer-aided strategy combining pharmacophore mapping and structure-based screening was used to screen the Maybridge and Enamine databases. Yeast two-hybrid (Y2H) assay was used to detect the activity and selectivity of the chosen compounds. The transcriptional activities of the chosen compounds were demonstrated with luciferase reporter assays. The anti-proliferative effects of ER antagonists against MCF-7 and MDA-MB-231 breast cancer cells were examined using MTT assay, and the mechanisms of action were analyzed with flow cytometry analysis and Western blotting. Results: Through in silico screen, 95 compounds were chosen for testing in Y2H assay, which led to 20 potent ligands, including 10 agonists, 8 antagonists and 2 partial agonists with EC 50 or IC 50 values at μmol/L. Furthermore, 6 agonists exhibited absolute selectivity for ERβ, and 3 agonists showed higher selectivity for ERβ. The agonists 1g and 1h (10, 25, and 50 μmol/L) dose-dependently increased ER transcriptional activities, whereas the antagonists 2a and 2d (10, 25, and 50 μmol/L) caused dose-dependent inhibition on the activities. The antagonists and partial agonists at 100 μmol/L suppressed the proliferation of ERα positive MCF-7 cells and ERβ positive MDA-MB-231 cells, but were more effective against MDA-MB-231 cells. Treatment of MDA-MB-231 cells with antagonists 2a and 2d (25 and 50 μmol/L) dose-dependently increased the population of cells in the S phase. Both 2a and 2d treatment dose-dependently decreased the expression levels of cyclin A and CDK2. Meanwhile, the downregulation of cyclin E was only caused by 2d , while 2a treatment did not cause significant changes in the protein levels of cyclin E. Conclusion: The selective ligands discovered in this study are promising drug candidates to be used as molecular probes to explore the differences between ERα and ERβ.

Recent Advances in Peptidomimetics Antagonists Targeting Estrogen Receptor Α-Coactivator Interaction in Cancer Therapy

New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives

Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer

Development of a Potent Peptide Inhibitor of Estrogen Receptor Α

Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

Selective Ligands of Estrogen Receptor Β Discovered Using Pharmacophore Mapping and Structure-Based Virtual Screening.

Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?

Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities

Discovery of ERD-12310A As an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor Α (Erα)

Structural Basis of Inhibition of ERα-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides.

Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using 3D-QSAR and Molecular Docking

Estrogen Receptor α/14-3-3 molecular glues as alternative treatment strategy for endocrine resistant breast cancer

Estrogen Receptor Alpha Binders for Hormone-Dependent Forms of Breast Cancer: e-QSAR and Molecular Docking Supported by X-ray Resolved Structures

Discovery of Estrogen Receptor Modulators: a Review of Virtual Screening and SAR Efforts

A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer